ELA026

DRUG4 trials

Sponsors

Electra Therapeutics Inc.

Conditions

Healthy VolunteersSecondary Hemophagocytic Lymphohistiocytosis (sHLH)T Cell Malignancies

Phase 1

Evaluation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ELA026 in Single and Multiple Doses in Healthy Volunteers

CompletedNCT05556863

Electra Therapeutics Inc.Healthy Volunteers

Start: 2021-10-18End: 2023-11-20Updated: 2024-03-27

A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)

RecruitingNCT07465835

Electra Therapeutics Inc.T Cell Malignancies

Start: 2026-02-17End: 2028-12-01Target: 84Updated: 2026-07-08

Phase 2

Open-label Study of ELA026 in Participants With Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

RecruitingNCT05416307

Electra Therapeutics Inc.Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

Start: 2022-05-19End: 2029-06-01Target: 156Updated: 2026-05-26

A Phase 2/3, Open-label, Single-arm, Multicenter, Historical Control Study to Evaluate ELA026 in Participants with Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

RecruitingCTIS2025-520624-25-00

Electra Therapeutics Inc.Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

Start: 2025-09-19Target: 40Updated: 2025-09-22

Related Papers

Encouraging Outcomes in Pediatric Malignancy‐Associated Hemophagocytic Lymphohistiocytosis: Results From the Italian <scp>HLH</scp> Registry

American Journal of Hematology2026-03-12

The surpass trial: a phase 2/3 registrational trial of ELA026 in subjects with treatment-Naïve secondary hemophagocytic lymphohistiocytosis

Blood2025-11-03

ELA026, a Monoclonal Antibody Targeting Signal Regulatory Protein-α/β1/γ, Rapidly Controls Inflammation and Improves 2-Month Survival in Treatment-Naïve Malignancy-Associated Hemophagocytic Lymphohistiocytosis

Blood2024-11-052 citations

A Phase 1b Study of ELA026, a Monoclonal Antibody Targeting Signal Regulatory Protein-α/β1/γ, in Patients with Newly Diagnosed and Previously Treated Secondary Hemophagocytic Lymphohistiocytosis

Blood2023-11-022 citations

PB2299: UPDATE ON TRIAL IN PROGRESS: A PHASE 1B STUDY OF ELA026 IN PATIENTS WITH SECONDARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (SHLH)

HemaSphere2023-08-01

Characterization of ELA026, a Clinical-Stage Monoclonal Antibody That Rapidly and Potently Depletes Myeloid Cells and T Lymphocytes

Blood2022-11-152 citations

Trial in Progress: A Phase 1b Study of ELA026 in Patients with Secondary Hemophagocytic Lymphohistiocytosis

Blood2022-11-151 citations